Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite intense research, it remains intriguing why hormonal therapies in general and progestins in particular sometimes fail in endometriosis. OBJECTIVE AND RATIONALE: We review here the action mechanisms of progesterone receptor ligands in endometriosis, identify critical differences between the effects of progestins on normal endometrium and endometriosis and envisage pathways to escape drug resistance and improve the therapeutic response of endometriotic lesions to such treatments. SEARCH METHODS: We performed a systematic Pubmed search covering articles published since 1958 about the use of progestins, estro-progestins and selective progesterone receptor modulators, to treat endometriosis and its related symptoms. Two reviewers screened the titles and abstracts to select articles for full-text assessment. OUTCOMES: Progesterone receptor signalling leads to down-regulation of estrogen receptors and restrains local estradiol production through interference with aromatase and 17 beta-hydroxysteroid dehydrogenase type 1. Progestins inhibit cell proliferation, inflammation, neovascularisation and neurogenesis in endometriosis. However, progesterone receptor expression is reduced and disrupted in endometriotic lesions, with predominance of the less active isoform (PRA) over the full-length, active isoform (PRB), due to epigenetic abnormalities affecting the PGR gene transcription. Oxidative stress is another mechanism involved in progesterone resistance in endometriosis. Among the molecular targets of progesterone in the normal endometrium that resist progestin action in endometriotic cells are the nuclear transcription factor FOXO1, matrix metalloproteinases, the transmembrane gap junction protein connexin 43 and paracrine regulators of estradiol metabolism. Compared to other phenotypes, deep endometriosis appears to be more resistant to size regression upon medical treatments. Individual genetic characteristics can affect the bioavailability and pharmacodynamics of hormonal drugs used to treat endometriosis and, hence, explain part of the variability in the therapeutic response. WIDER IMPLICATIONS: Medical treatment of endometriosis needs urgent innovation, which should start by deeper understanding of the disease core features and diverse phenotypes and idiosyncrasies, while moving from pure hormonal treatments to drug combinations or novel molecules capable of restoring the various homeostatic mechanisms disrupted by endometriotic lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, they have antiestrogenic effect causing endometrial pseudodecidualisation, inhibit inflammatory response, provoke apoptosis of endometriotic cells, reduce oxidative stress, inhibit angiogenesis and suppress expression of matrix metalloproteinases [5, 26] (Fig. 4).”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reis et al. [56] summarized the effect of progestins on endometriotic lesions as generating different levels of downregulation of ERs, a drop in local E2 production, a reduction in inflammation, and creation of a pseudo-pregnancy condition.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [56]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“the risk of venous or arterial thrombosis is not negligible [54,55,56,57,58,59,60,61,62,63,64,65,66,67].”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [56]
Experimental — accuracy not yet measuredIn the citing paper
“A recent review by Reis et al. [56] also confirms that deep endometriosis appears to be more resistant to regression upon medical treatment.”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [56]
In the citing paper
“In the present paper, we thoroughly scrutinized the concept of progesterone resistance as an explanation for why 33% of patients do not respond to OCPs and progestins, with this percentage climbing even higher in women with deep nodular endometriosis [46,47,56,58].”
From Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review (2021) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
VINCI, G., Arkwright, S., Audebourg, A., Radenen, B., Chapron, C., Borghese, B., Dousset, B. E., Méhats, C., Vaiman, D., Vacher‐Lavenu, M., et al. (2016) · Reproductive Sciences · doi:10.1177/1933719116638188 · Cited by 10
Self-citationViganò, P., Blasio, A. M. D., Busacca, M., & Vignali, M. (1994) · Gynecological Endocrinology · doi:10.3109/09513599409028452 · Cited by 9
Taneja, A., Kaur, S., Soni, R. K., Bhanupriya, Kaur, J., & Singla, L. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/24126.10272 · Cited by 9
Rekers, N. V., Flaig, T., Mallat, M. J. K., Spruyt-Gerritse, M. J., Zandbergen, M., Anholts, J. D. H., Bajema, I. M., Groningen, M. C. C., Yang, J., de Fijter, J. W., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001584 · Cited by 8
Oral contraceptives and pituitary response to GnRH: Comparative study of progestin-related effects
Römmler, A., Baumgarten, S., Moltz, L., Schwartz, U., & Hammerstein, J. (1985) · Contraception · doi:10.1016/0010-7824(85)90098-8 · Cited by 7
Intérêt actuel des selective progesterone receptor modulators (SPRM) dans l’endométriose
Merviel, P., Lourdel, E., Sanguin, S., Gagneur, O., Cabry, R., & Nasreddine, A. (2013) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2013.07.016 · Cited by 7
Effects of different progestins on prostaglandin biosynthesis in human endometrial explants
Roth, K., Zahradnik, H. P., & Schäfer, W. (2018) · Contraception · doi:10.1016/j.contraception.2018.08.001 · Cited by 6
Progestins for the Treatment of Endometriosis: An Update
Lazzeri, L., Luisi, S. V., & Petraglia, F. (2010) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.1177/228402651000200401 · Cited by 5
Self-citationHorne, A. W., & Critchley, H. (2011) · Wiley eBooks · doi:10.1002/9781444398519.ch34 · Cited by 4
Progestins for the Treatment of Endometriosis: An Update:
Lazzeri, L., Luisi, S. V., & Petraglia, F. (2010) · Florence Research (University of Florence) · doi:10.5301/je.2010.6203 · Cited by 3
Self-citation
Research works printed but not linked: 4
- Andrews, 1976, Hormone therapy of endometriosis - estrogen, androgens, progestin estrogens, Excerpta Med, 368, 46
- Gerdes, 1998, Cloning and tissue expression of two putative steroid membrane receptors, Biol Chem, 379, 907
- Iskhakova, 2006, Polymorphism of the arylamine-n-acetyltransferase gene in endometriosis patients in the Republic of Bashkortostan, Balk J Med Genet, 9, 55
- Rokitansky, 1860, Über Uterusdrüsen-Neubildungen in Uterus- und Ovarial-Sarcomen, Zeitschrift der Kaiserlich Koenigl Gesellschaft der Aerzte zu Wien, 37, 577
Cited by
Endometriosis: Etiology, pathobiology, and therapeutic prospects
Saunders, P. T. K., & Horne, A. W. (2021) · Cell · doi:10.1016/j.cell.2021.04.041 · Cited by 961
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
“The pathophysiology of endometriosis is still a matter of investigation, but endocrine and inflammatory backgrounds are well characterized, recognizing an estrogen-dependency [4] and a progesterone-resistance [5].”
BackgroundSelf-citationDonnez, J., & Dolmans, M.-M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10051085 · Cited by 182
Progesterone Actions and Resistance in Gynecological Disorders
MacLean, J. A., & Hayashi, K. (2022) · Cells · doi:10.3390/cells11040647 · Cited by 176
“While PRA and PRB isoforms are detected in human eutopic endometrium with endometriosis during the menstrual cycle, both the expression of PRA and PRB are generally lower in any type of ectopic lesions [56].”
BackgroundProgesterone Resistance in Endometriosis: Current Evidence and Putative Mechanisms
Zhang, P., & Wang, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086992 · Cited by 162
Metadata
- Authors
- Reis, F. M., Coutinho, L. M., Vannuccini, S., Batteux, F., Chapron, C., & Petraglia, F.
- Affiliations
- Universidade Federal de Minas Gerais (BR)
- University of Siena (IT)
- Inserm (FR)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Corresponding author
- Petraglia, Felice
- ORCID
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-16
- Volume
- 26
- Issue
- 4
- Pages
- 565-585
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- PMC
- PMC7317284
- OpenAlex
- W3026807961
- Cited by
- 166
- References
- 210
- Citations by year
- 2026: 30 · 2025: 23 · 2024: 29 · 2023: 26 · 2022: 27 · 2021: 30 · 2020: 1
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Human Reproduction Update (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (201876/2017-5)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- endometriosis, progesterone receptor, progestins, selective progesterone receptor modulators, drug resistance, progesterone receptor isoforms, epigenetic regulation, oxidative stress, FOXO1, matrix metalloproteinases, connexin 43, aromatase, estradiol metabolism, deep infiltrating endometriosis, endometriosis phenotypes, hormone therapy
- MeSH terms
- Endometriosis, Endometrium, Female, Fertility Agents, Female, Humans, Ligands, Peritoneal Diseases, Progestins, Progesterone, Receptors, Progesterone, Uterine Diseases, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.